Hyperlipidemia Global Market Report 2024

The global hyperlipidemia market has grown steadily in recent years. It will grow from $19.41 billion in 2023 to $20.24 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to growing demand for effective treatments, geographic expansion, growing public awareness of hyperlipidemia, tobacco use.

The global hyperlipidemia market is expected to see steady growth in the next few years. It will grow to $23.25 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.

The anticipated growth of the hyperlipidemia market is attributed to the rising prevalence of chronic illnesses, notably heart disease. Heart diseases encompass a range of conditions that impact the functioning of the heart. Hyperlipidemia treatments play a pivotal role in assisting individuals dealing with heart disease by reducing the risk of heart attacks, preventing strokes, enhancing endothelial function, and decreasing the necessity for invasive medical procedures. As an example, in March 2022, data from The Office for National Statistics, a governmental agency in the UK, revealed an increase in the number of deaths due to heart attacks, rising from 19,440 in 2020 to 20,061 in 2021. Consequently, the growing incidence of chronic conditions like heart disease serves as a driving force behind the expansion of the hyperlipidemia market.

The increasing prevalence of smoking is expected to drive the growth of the hyperlipidemia market in the future. Smoking involves the consumption of tobacco through combustion, leading to the inhalation of smoke and the absorption of various components into the bloodstream. Smoking is closely linked to risk factors associated with hyperlipidemia, such as obesity and insulin resistance. These risk factors can contribute to dyslipidemia, characterized by abnormal lipid levels, which can eventually lead to the development of hyperlipidemia. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales reaching 1.4 billion in June 2022. Therefore, the growing prevalence of smoking is a driving factor in the hyperlipidemia market.

The side effects of medications, particularly with treatments like statin therapy for hyperlipidemia, present a challenge and may impede the market's growth during the forecast period. Statin therapy is a commonly used treatment for hyperlipidemia, but it can lead to side effects such as muscle inflammation and, in rare cases, more serious conditions like Rhabdomyolysis. For example, in September 2022, there were approximately 1 in 10,000 cases of Rhabdomyolysis, a condition characterized by severe muscle inflammation and damage, as a severe side effect associated with statin therapy for hyperlipidemia. Consequently, the side effects of medications, particularly those related to treatments like statin therapy, are hindering the growth of the hyperlipidemia market.

Prominent companies in the hyperlipidemia market are concentrating on the development of innovative products, including advanced lipid-lowering therapies, to maintain their competitive edge. An illustrative case is Novartis, a pharmaceutical company headquartered in the United States, which introduced a novel hyperlipidemia medication named Leqvio (inclisiran) in December 2021. This medication received approval from the Food and Drug Administration, a U.S.-based governmental agency. Notably, Leqvio represents a pioneering siRNA (small interfering RNA) drug designed for cholesterol reduction, serving as an adjunct therapy alongside dietary measures and statin treatment for adults afflicted by clinical atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) necessitating additional reduction of low-density lipoprotein cholesterol (LDL-C).

In March 2022, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology firm, finalized the acquisition of Arena Pharmaceuticals for an undisclosed sum. This strategic move by Pfizer is driven by the company's goal of broadening its product portfolio through the addition of Arena Pharmaceuticals' ongoing clinical-stage projects, which hold promise for the advancement of innovative therapies targeting various immuno-inflammatory diseases. Arena Pharmaceuticals, situated in the United States, is recognized for its specialization in biopharmaceuticals and the development of medications, including those designed to address high cholesterol and hyperlipidemia.

Major players in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S.

North America was the largest region in the hyperlipidemia market in 2023. The regions covered in hyperlipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hyperlipidemia can be classified into two main types such as familial and acquired. Familial hyperlipidemia is a genetic disorder characterized by hereditary high lipid levels, notably cholesterol and triglycerides, significantly increasing the risk of cardiovascular diseases. Treatment options encompass medications like statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and others. These medications can be administered orally or through injection. They serve various end-users, including hospitals, specialty clinics, home care services, and more.

This report provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.